Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial

BACKGROUND: Intestinal microbiota restoration can be achieved by complementing a subject’s perturbed microbiota with that of a healthy donor. Recurrent Clostridioides difficile infection (rCDI) is one key application of such treatment. Another emerging application of interest is reducing antibiotic-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwak, Suryang, Choi, JooHee, Hink, Tiffany, Reske, Kimberly A., Blount, Kenneth, Jones, Courtney, Bost, Margaret H., Sun, Xiaoqing, Burnham, Carey-Ann D., Dubberke, Erik R., Dantas, Gautam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457799/
https://www.ncbi.nlm.nih.gov/pubmed/32862830
http://dx.doi.org/10.1186/s40168-020-00907-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457799/
https://www.ncbi.nlm.nih.gov/pubmed/32862830
http://dx.doi.org/10.1186/s40168-020-00907-9

Ejemplares similares